162 related articles for article (PubMed ID: 32854385)
1. Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer.
Sundralingam U; Chakravarthi S; Radhakrishnan AK; Muniyandy S; Palanisamy UD
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32854385
[TBL] [Abstract][Full Text] [Related]
2. Ratite oils for local transdermal therapy of 4-OH tamoxifen: development, characterization, and
Sundralingam U; Muniyandy S; Radhakrishnan AK; Palanisamy UD
J Liposome Res; 2021 Sep; 31(3):217-229. PubMed ID: 32648792
[TBL] [Abstract][Full Text] [Related]
3. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
6. In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast.
Lee O; Ivancic D; Chatterton RT; Rademaker AW; Khan SA
Breast Cancer (Dove Med Press); 2011; 3():61-70. PubMed ID: 24367176
[TBL] [Abstract][Full Text] [Related]
7. Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis.
Sundralingam U; Khan TM; Elendran S; Muniyandy S; Palanisamy UD
Pak J Pharm Sci; 2019 May; 32(3):1121-1128. PubMed ID: 31278729
[TBL] [Abstract][Full Text] [Related]
8. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
9. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
10. Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Lee O; Khan SA
Semin Oncol; 2016 Feb; 43(1):107-115. PubMed ID: 26970129
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-mass spectrometry method for the quantification of tamoxifen and its metabolite 4-hydroxytamoxifen in rat plasma: application to interaction study with biochanin A (an isoflavone).
Singh SP; Wahajuddin ; Ali MM; Kohli K; Jain GK
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Oct; 879(27):2845-51. PubMed ID: 21890435
[TBL] [Abstract][Full Text] [Related]
12. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
13. Double-Blind, Placebo-Controlled Pilot Study of Processed Ultra Emu Oil Versus Placebo in the Prevention of Radiation Dermatitis.
Rollmann DC; Novotny PJ; Petersen IA; Garces YI; Bauer HJ; Yan ES; Wahner-Roedler D; Vincent A; Sloan JA; Issa Laack NN
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):650-8. PubMed ID: 25936812
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Teunissen SF; Jager NG; Rosing H; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jun; 879(19):1677-85. PubMed ID: 21543272
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex.
Lin YL; Chen CH; Wu HY; Tsai NM; Jian TY; Chang YC; Lin CH; Wu CH; Hsu FT; Leung TK; Liao KW
J Nanobiotechnology; 2016 Feb; 14():11. PubMed ID: 26892504
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
17. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
18. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro.
Boocock DJ; Maggs JL; White IN; Park BK
Carcinogenesis; 1999 Jan; 20(1):153-60. PubMed ID: 9934863
[TBL] [Abstract][Full Text] [Related]
19. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
Zhong Q; Zhang C; Zhang Q; Miele L; Zheng S; Wang G
BMC Cancer; 2015 Sep; 15():625. PubMed ID: 26354796
[TBL] [Abstract][Full Text] [Related]
20. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
